Citadel Advisors LLC boosted its holdings in shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) by 304.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,270 shares of the biotechnology company’s stock after acquiring an additional 31,070 shares during the period. Citadel Advisors LLC owned 0.23% of Applied Genetic Technologies worth $163,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in AGTC. Trexquant Investment LP boosted its holdings in Applied Genetic Technologies by 3.2% in the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 611 shares during the last quarter. Nine Chapters Capital Management LLC acquired a new position in Applied Genetic Technologies in the 3rd quarter valued at about $113,000. Virtu KCG Holdings LLC acquired a new position in Applied Genetic Technologies in the 2nd quarter valued at about $178,000. Credit Suisse AG boosted its holdings in Applied Genetic Technologies by 10.9% in the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,662 shares during the last quarter. Finally, LMR Partners LLP acquired a new position in Applied Genetic Technologies in the 2nd quarter valued at about $275,000. 47.02% of the stock is owned by institutional investors.
Several equities analysts have weighed in on AGTC shares. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. Stifel Nicolaus decreased their price objective on shares of Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, September 14th. Cantor Fitzgerald set a $9.00 price objective on shares of Applied Genetic Technologies and gave the stock a “hold” rating in a report on Friday, October 6th. Wedbush restated an “outperform” rating and issued a $9.00 price objective on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $7.00 price objective (down from $14.00) on shares of Applied Genetic Technologies in a report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Applied Genetic Technologies presently has an average rating of “Hold” and a consensus target price of $10.17.
Applied Genetic Technologies (NASDAQ:AGTC) last issued its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.40). The company had revenue of $8.30 million during the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. The business’s revenue was down 31.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.15 earnings per share. equities research analysts anticipate that Applied Genetic Technologies Corporation will post -1.14 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Citadel Advisors LLC Increases Position in Applied Genetic Technologies Corporation (AGTC)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/17/citadel-advisors-llc-increases-position-in-applied-genetic-technologies-corporation-agtc.html.
Applied Genetic Technologies Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corporation (NASDAQ:AGTC).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.